Amycretin: The GLP-1/Amylin Dual Agonist Trial Explained
TRIAL-000022
Direct Answer
Amycretin is a real, investigational Novo Nordisk drug, a single molecule combining GLP-1 and amylin receptor agonism, developed in both once-daily oral and once-weekly injectable forms. It is not FDA-approved.
Real, Reported Phase 2 Results
A Phase 1b/2a trial published in The Lancet found subcutaneous amycretin produced roughly 14.5-15.2% mean weight loss over 26-36 weeks, with participants still losing weight at the study's end. Earlier oral-formulation data showed a 13.1% reduction over 12 weeks at the highest dose tested.
Why the Combination Matters
GLP-1 and amylin act through different, complementary neural pathways, GLP-1 primarily via vagal afferents, amylin via the area postrema, a real, mechanistic rationale for combining them rather than simply increasing GLP-1 dosing alone.
Current, Real Status
Novo Nordisk has advanced both formulations to Phase 3 trials for weight management based on these results. Amycretin is not available for human use in the United States.
References
- Dahl K, et al., The Lancet (2025): Amycretin Phase 1b/2a trial results
- Novo Nordisk: official Phase 3 advancement announcement (2026)
How Amycretin Compares to CagriSema
| Drug | Design | Real Weight Loss (Phase 2) |
|---|---|---|
| CagriSema | Two separate molecules, co-formulated | ~20.4-22.7% |
| Amycretin | Single unimolecular design | ~14.5-15.2% |
Both target the same amylin pathway using genuinely different real approaches, CagriSema co-formulates two separate molecules, while amycretin is a single, unimolecular design. See DietApp's REDEFINE trials page for CagriSema for the direct comparison.
Frequently Asked Questions
Why combine GLP-1 with amylin specifically? The two hormones act through different, complementary brain pathways, GLP-1 via vagal afferents, amylin via the area postrema in the brainstem, near the hypothalamus, a real, mechanistic rationale for combining them.
Is the oral form of amycretin as effective as the injectable? Not yet established; oral absorption remains a genuine pharmaceutical challenge, similar to what limited early oral semaglutide.
Is amycretin approved anywhere? No, it remains investigational globally, currently in Phase 3.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.
amycretin-the-glp-1-amylin-dual-agonist-trial-explained